Humana (NYSE:HUM) Now Covered by Evercore ISI

Evercore ISI assumed coverage on shares of Humana (NYSE:HUM) in a research note released on Monday morning, Marketbeat reports. The firm issued an in-line rating and a $295.00 price target on the insurance provider’s stock.

Other analysts also recently issued research reports about the company. Wall Street Zen downgraded Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Wells Fargo & Company lowered their target price on Humana from $348.00 to $344.00 and set an “overweight” rating on the stock in a research report on Thursday, August 14th. Bank of America lifted their target price on Humana from $285.00 to $312.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Barclays lifted their target price on Humana from $275.00 to $315.00 and gave the company an “equal weight” rating in a research report on Friday, September 5th. Finally, Piper Sandler lowered their price target on Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a research report on Thursday, July 31st. Seven investment analysts have rated the stock with a Buy rating and seventeen have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $289.50.

Humana Stock Performance

Shares of Humana stock opened at $258.09 on Monday. The firm has a market cap of $31.04 billion, a price-to-earnings ratio of 19.81, a price-to-earnings-growth ratio of 1.48 and a beta of 0.44. The stock’s 50-day moving average is $269.18 and its 200-day moving average is $257.22. Humana has a one year low of $206.87 and a one year high of $324.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the firm earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Equities analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, September 26th. Humana’s payout ratio is 27.17%.

Institutional Investors Weigh In On Humana

Several institutional investors have recently made changes to their positions in the stock. Caldwell Trust Co bought a new stake in shares of Humana in the second quarter valued at approximately $152,000. Orion Porfolio Solutions LLC lifted its stake in Humana by 3.6% during the second quarter. Orion Porfolio Solutions LLC now owns 6,979 shares of the insurance provider’s stock worth $1,706,000 after purchasing an additional 241 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Humana during the second quarter worth $201,000. State of Wyoming lifted its stake in Humana by 391.5% during the second quarter. State of Wyoming now owns 4,178 shares of the insurance provider’s stock worth $1,021,000 after purchasing an additional 3,328 shares during the last quarter. Finally, Pitcairn Co. lifted its stake in Humana by 75.2% during the second quarter. Pitcairn Co. now owns 1,777 shares of the insurance provider’s stock worth $434,000 after purchasing an additional 763 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.